Holen Sie sich die Stockscreener-App
1.1904
0.80%
-0.0096
Schlusskurs vom Vortag:
$1.20
Offen:
$1.2
24-Stunden-Volumen:
64,044
Relative Volume:
0.13
Marktkapitalisierung:
$2.75M
Einnahmen:
$35.75M
Nettoeinkommen (Verlust:
$11.57M
KGV:
-0.3127
EPS:
-3.8069
Netto-Cashflow:
$-26.25M
1W Leistung:
-26.97%
1M Leistung:
-41.36%
6M Leistung:
-79.55%
1J Leistung:
-92.54%
1-Tages-Spanne:
$1.18
$1.23
1-Wochen-Bereich:
$1.1758
$1.72
52-Wochen-Spanne:
$1.1758
$15.33
Redhill Biopharma Ltd Adr Stock (RDHL) Company Profile
Vergleichen Sie RDHL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RDHL
Redhill Biopharma Ltd Adr
|
1.1999 | 2.75M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
ZTS
Zoetis Inc
|
151.55 | 65.61B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.23 | 44.72B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.50 | 43.39B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.66 | 17.64B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
293.19 | 13.31B | 2.99B | 1.21B | 1.13B | 25.06 |
Redhill Biopharma Ltd Adr Stock (RDHL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-08-31 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-05-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-09-11 | Eingeleitet | BTIG Research | Buy |
| 2019-07-12 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2019-03-12 | Hochstufung | WBB Securities | Speculative Buy → Buy |
| 2018-01-26 | Eingeleitet | Nomura | Buy |
| 2017-10-06 | Eingeleitet | Seaport Global Securities | Buy |
| 2017-10-04 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-24 | Bestätigt | FBR & Co. | Outperform |
| 2016-07-27 | Bestätigt | FBR Capital | Outperform |
| 2015-09-29 | Eingeleitet | Nomura | Buy |
| 2015-07-29 | Bestätigt | ROTH Capital | Buy |
| 2015-06-17 | Bestätigt | H.C. Wainwright | Buy |
| 2015-06-15 | Bestätigt | ROTH Capital | Buy |
Alle ansehen
Redhill Biopharma Ltd Adr Aktie (RDHL) Neueste Nachrichten
Redhill Biopharma stock soars after FDA provides positive pathway for Crohn’s drug - Investing.com India
Taking the lead: Redhill Biopharma Ltd. ADR (RDHL) - Sete News
The time has not yet come to remove your chips from the table: Hertz Global Holdings Inc (HTZ) - Sete News
A significant driver of top-line growth: Alexandria Real Estate Equities Inc (ARE) - Sete News
Redhill Biopharma Ltd. ADR [RDHL] Insider Activity: An Update for Investors - knoxdaily.com
RedHill Biopharma faces Nasdaq non-compliance issue - Investing.com
RedHill Biopharma faces Nasdaq non-compliance issue By Investing.com - Investing.com India
RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency - PR Newswire
Redhill Biopharma stock hits 52-week low at $1.72 amid market challenges - Investing.com
Redhill Biopharma stock hits 52-week low at $2.47 amid steep annual decline - Investing.com
RedHill Biopharma targets UK approval for H. pylori therapy - Investing.com India
RedHill Biopharma targets UK approval for H. pylori therapy By Investing.com - Investing.com South Africa
Redhill Biopharma Ltd. ADR (RDHL)’s Stock Price Falls Due To Weak Fundamental Momentum - Marketing Sentinel
Redhill Biopharma stock hits 52-week low at $3 amid steep annual decline By Investing.com - Investing.com South Africa
Redhill Biopharma stock hits 52-week low at $3 amid steep annual decline - Investing.com
What Did We Note About Insider Trading At Redhill Biopharma Ltd. ADR (NASDAQ: RDHL)? - Stocks Register
Hyloris secures global rights to RedHill’s RHB-102 - Investing.com India
Redhill Biopharma stock hits 52-week low at $4.79 - Investing.com India
Earnings call transcript: RedHill Biopharma Q1 2022 sees revenue dip - Investing.com
RedHill tests opaganib with Bayer's drug in prostate cancer study By Investing.com - Investing.com South Africa
RedHill tests opaganib with Bayer's drug in prostate cancer study - Investing.com India
RedHill stock rises on expanded Medicare coverage By Investing.com - Investing.com South Africa
RedHill wins $8 million judgment in New York court - Investing.com
RedHill Biopharma Announces Plan to Implement ADS Ratio Change - PR Newswire
symbol__ Stock Quote Price and Forecast - CNN
Balancing Acidity: Exploring the Proton Pump Inhibitors Market - openPR.com
RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S. - Barchart.com
RedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross Proceeds - Barchart.com
RedHill Biopharma to Implement ADS Ratio Change to 1:400 By Investing.com - Investing.com India
Why Beyond Meat Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket - markets.businessinsider.com
Extremely Robust COVID-19 Clinical Trial Pipeline With 420+ Key Companies Expected to Change the Pace of the COVID-19 Treatment - PR Newswire UK
Cathie Wood Predictions 2022 - New Trader U
RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D - PR Newswire
AstraZeneca divestment of Movantik to RedHill Biopharma completed - AstraZeneca
RedHill Biopharma to Focus Commercial Efforts on Talicia® - GlobeNewswire
RedHill Biopharma: TALICIA Launch For H. Pylori In Sight - Investing.com
RedHill Biopharma's Drug Pipeline May Merit Substantial Upside, And Potential Catalysts Are On The Horizon - Seeking Alpha
RedHill Biopharma files for further Nasdaq offering - גלובס
Redhill Biopharma (RDHL) Stock Price, News & Analysis - MarketBeat
Finanzdaten der Redhill Biopharma Ltd Adr-Aktie (RDHL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.02%
1.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):